RELIEF THERAPEUTICS HOLDING AG

ISIN: CH1251125998 WKN: 125112599 Asset Class: Stock



Company Profile

RELIEF THERAPEUTICS Holding SA is a commercial-stage biopharmaceutical company, which engages in the research, development, and commercialization of treatment for rare debilitating conditions. The firm offers Physiomimic and TEHCLO, drug delivery platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets to address rare metabolic disorders, rare skin diseases, and rare respiratory diseases. It operates through the following geographical segments: Switzerland, Europe, North America, and Rest of the World. The company was founded in 2013 and is headquartered in Geneva, Switzerland.

	20	23	20	22	20	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	18,304,000		22,583,000		54,970,000	
Common stock capital		56,163,000		56,163,000		44,133,000
Fixed assets	58,086,000		166,215,000		196,648,000	
Equity capital of a company		52,228,000		145,417,000		181,530,000
Cash and cash equivalents	14,556,000		19,237,000		44,761,000	
Accrued liabilities		7,792,000		9,681,000		22,263,000
Other assets	-		-		-	
Current liabilities		6,909,000		10,716,000		19,733,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		17,253,000		32,665,000		50,355,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	76,390,000	76,390,000	188,798,000	188,798,000	251,618,000	251,618,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	-	-
Equity ratio	68.37%	77.02%	72.15%
Debt-equity ratio	46.26%	29.83%	38.61%

Others	0	tl	ıе	r
--------	---	----	----	---

	2023	2022	2021
Tax Expense Rate	12.09%	6.49%	2.31%

RELIEF THERAPEUTICS HOLDING AG

ISIN: CH1251125998 WKN: 125112599 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	6,033,000	6,081,000	3,321,000
Net income	-98,181,000	-50,790,000	-34,705,000
EBIT	-116,791,843	-56,650,003	-36,934,781
Operating income before taxes	-111,684,000	-54,316,000	-35,525,000
Cash Flow	-17,519,000	-24,108,000	-35,711,000
Net interest income	-71,000	-178,000	-228,000
Research and development expenses	1,328,000	12,393,000	19,024,000
Income taxes	-13,503,000	-3,526,000	-820,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	-	-	-

Board of Directors	
Gregory Van Beek	Member of the administrative board
Peter Egon de Svastich	Member of the administrative board
Tommy Elzinga	Member of the administrative board
Raghuram Selvaraju	Chairman of the administrative boar

Members of Management Board				
Andrew Einhorn	Member of Executive Committee			
Anthony Kim	Member of Executive Committee			
Giorgio Reiner	Member of Executive Committee			
Melinda Keegan	Member of Executive Committee			
Paolo Galfetti	Member of Executive Committee			
Vincenzo Gallo	Member of Executive Committee			